Brii Biosciences-B (02137) Announces Latest Breakthrough Data from ENRICH and ENHANCE Phase II Studies at the 2026 AASLD Annual Meeting

Zhitong Finance APP News, Brii Biosciences-B (02137) announced that the company presented the end-of-treatment (EOT) and follow-up results of its Phase IIb ENRICH and ENHANCE studies in three late-breaking oral presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, held in Denver, Colorado, USA, from November 5 to 9, 2026.